BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.060
-0.030 (-2.75%)
At close: Apr 28, 2026, 4:00 PM EDT
1.040
-0.020 (-1.89%)
Pre-market: Apr 29, 2026, 4:28 AM EDT
BioXcel Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 0.64 | 2.27 | 1.38 | 0.38 | - | |
| Revenue Growth (YoY) | -71.67% | 64.20% | 268.00% | - | - | |
| Cost of Revenue | 0.16 | 2.14 | 1.26 | 0.02 | - | |
| Gross Profit | 0.48 | 0.12 | 0.12 | 0.36 | - | |
| Selling, General & Admin | 20.49 | 34.49 | 83.41 | 68.76 | 54.59 | |
| Research & Development | 30.25 | 30.44 | 84.33 | 91.24 | 52.34 | |
| Operating Expenses | 50.75 | 64.93 | 167.74 | 160 | 106.94 | |
| Operating Income | -50.27 | -64.8 | -167.62 | -159.65 | -106.94 | |
| Interest Expense | -16.98 | -15.13 | -13.31 | -8.21 | -0.04 | |
| Interest & Investment Income | 1.07 | 2.6 | 5.65 | 2.53 | 0.04 | |
| Other Non Operating Income (Expenses) | -3.52 | 20.17 | 0.39 | -0.43 | - | |
| EBT Excluding Unusual Items | -69.7 | -57.16 | -174.89 | -165.76 | -106.93 | |
| Merger & Restructuring Charges | -0.19 | -2.44 | -4.16 | - | - | |
| Pretax Income | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 | |
| Net Income | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 | |
| Net Income to Common | -69.9 | -59.6 | -179.05 | -165.76 | -106.93 | |
| Shares Outstanding (Basic) | 12 | 3 | 2 | 2 | 2 | |
| Shares Outstanding (Diluted) | 12 | 3 | 2 | 2 | 2 | |
| Shares Change (YoY) | 381.58% | 39.21% | 4.00% | 6.23% | 21.63% | |
| EPS (Basic) | -5.73 | -23.51 | -98.33 | -94.67 | -64.87 | |
| EPS (Diluted) | -5.73 | -23.51 | -98.33 | -94.67 | -64.87 | |
| Free Cash Flow | -57.62 | -72.03 | -155.03 | -135.48 | -82.6 | |
| Free Cash Flow Per Share | -4.72 | -28.41 | -85.13 | -77.38 | -50.11 | |
| Gross Margin | 74.45% | 5.43% | 8.70% | 94.67% | - | |
| Operating Margin | -7829.75% | -2859.84% | -12146.30% | -42572.00% | - | |
| Profit Margin | -10887.38% | -2630.14% | -12974.85% | -44201.87% | - | |
| Free Cash Flow Margin | -8974.30% | -3178.60% | -11233.77% | -36128.00% | - | |
| EBITDA | -49.97 | -64.5 | -167.3 | -159.32 | -106.64 | |
| D&A For EBITDA | 0.3 | 0.31 | 0.32 | 0.33 | 0.3 | |
| EBIT | -50.27 | -64.8 | -167.62 | -159.65 | -106.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.